RESEARCH ARTICLE

Thai-Lepto-on-admission probability (THAI-LEPTO) score as an early tool for initial diagnosis of leptospirosis: Result from Thai-Lepto AKI study group

Theerapon Sukmark1, Nuttha Lumlertgul2, Sadudee Peerapornratana2,3, Kamol Khositrangsikun4, Kriang Tungsanga2, Visith Sitprija5, Nattachai Srisawat2,3*, Thai-Lepto AKI study group

1 Thungsong hospital, Nakhon Si Thammarat, Thailand, 2 Division of Nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, and King Chulalongkorn Memorial Hospital, Bangkok, Thailand, 3 Center for Critical Care Nephrology, The CRISMA Center, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America, 4 Maharaj Nakhon Si Thammarat hospital, Nakhon Si Thammarat, Thailand, 5 Queen Saovabha Memorial Institute, Thai Red Cross, Bangkok, Thailand

¶ Membership of the Thai-Lepto AKI study group is listed in the Acknowledgments section of this paper.

* drnattachai@yahoo.com

Abstract

Background

Leptospirosis is one of the most important zoonosis in the tropics. Currently, specific laboratory diagnostic test for leptospirosis such as polymerase chain reaction (PCR) or direct culture cannot be applied at the primary care setting especially in the resource-limited countries. Therefore, clinical presentation and laboratory examination are still the primary diagnostic tools for leptospirosis.

Objectives

To detect clinical factors for predicting leptospirosis in suspected cases, and to create a clinical prediction score (THAI-LEPTO) that is practical and easy to use in general practice while awaiting laboratory results.

Materials and methods

We performed a prospective multicenter study with a development and a validation cohort of patients presenting with clinical suspicion of leptospirosis as per the WHO clinical criteria. The development cohort was conducted at 11 centers in 8 provinces around Thailand. The validation cohort was conducted at 4 centers in 1 province from the Northeastern part of Thailand. Leptospirosis confirmed cases were defined if any one of the tests were positive: microscopic agglutination test, direct culture, or PCR technique. Multivariable logistic regression was used to identify predictors of leptospirosis. The clinical prediction score was derived from the regression coefficients (original) or from the odds ratio values (simplified).
We used receiver operating characteristic (ROC) curve analysis to evaluate the diagnostic ability of our score and to find the optimal cutoff values of the score. We used a validation cohort to evaluate the accuracy of our methods.

**Results**

In the development cohort, we enrolled 221 leptospirosis suspected cases and analyzed 211. Among those, 105 (50%) were leptospirosis confirmed cases. In logistic regression adjusted for age, gender, day of fever, and one clinical factor at a time, leptospirosis group had more hypotension OR = 2.76 (95% CI 1.07–7.10), jaundice OR = 3.40 (95% CI 1.48–8.44), muscle pain OR = 2.12 (95% CI 1.06–4.26), acute kidney injury (AKI) OR = 2.90 (95% CI 1.31–6.15), low hemoglobin OR = 3.48 (95% CI 1.72–7.04), and hypokalemia with hyponatremia OR = 3.56 (95% CI 1.17–10.84) than non-leptospirosis group. The aforementioned factors along with neutrophilia and pulmonary opacity were used in the development of the score. The simplified score with 7 variables was the summation of the odds ratio values as follows: hypotension 3, jaundice 2, muscle pain 2, AKI 1.5, low hemoglobin 3, hypokalemia with hyponatremia 3, and neutrophilia 1. The score showed the highest discriminatory power with area under the curve (AUC) 0.82 (95% CI 0.67–0.97) on fever day 3–4. In the validation cohort we enrolled 96 leptospirosis suspected cases and analyzed 92. Of those, 69 (75%) were leptospirosis confirmed cases. The performance of the simplified score with 7 variables at a cutoff of 4 was AUC 0.78 (95% CI 0.68–0.89); sensitivity 73.5; specificity 73.7; positive predictive value 87.8; negative predictive value 58.3.

**Conclusions**

THAI-LEPTO score is a newly developed diagnostic tool for early presumptive diagnosis of leptospirosis in patients presenting with severe clinical suspicion of the disease. The score can easily be applied at the point of care while awaiting confirmatory laboratory results. Each predictor used has been supported by evidence of clinical and pathophysiological correlation.

**Author summary**

Leptospirosis is an important zoonosis in the tropics. However, there is still a major barrier of early diagnosis of leptospirosis due to a lack of specific and sensitive testing. Moreover, in resource-limited countries with small budgets, a simple and cheap diagnostic test is essential for the diagnosis of leptospirosis. The THAI-LEPTO score has been developed and validated based on the relevant clinical history and related laboratory test. This score will help the physician in early diagnosis and prompt treatment leptospirosis as a point of care test. Finally, we aim that this scoring system can be one of the key parts of diagnostic algorithm and improve leptospirosis patients’ outcome.

**Introduction**

Leptospirosis is a common zoonosis that can occur worldwide but is mostly found in tropical regions. Several mammals are natural hosts and humans are infected after environmental or
animal contact. In Thailand, after a severe flood in 2000 a large outbreak of leptospirosis occurred and resulted in a total of 14,285 cases or 23 cases per 100,000 population. The background prevalence of leptospirosis in Thailand has been 3,000–4,000 cases per year (or 5 cases per 100,000 population) [1].

Inexperienced physicians are reluctant to make a presumptive diagnosis of leptospirosis because its clinical presentation can be similar to many other infectious diseases such as rickettsial infection, dengue hemorrhagic fever, malaria, influenza, and bacterial sepsis. To alleviate disease severity early diagnosis is key in allowing early treatment. However, current diagnostic tests such as direct culture, rapid tests for antibody detection, and other serological tests are insensitive during the early phase of leptospirosis infection [2–5]. Moreover, polymerase chain reaction (PCR) testing is still expensive and difficult to apply in a primary health care setting. Inevitably, at the point of care, most physicians still need to use initial clinical presentations as the primary tool to diagnose leptospirosis. Unfortunately, the diagnostic performance of Faine’s criteria [6] for presumptive diagnosis of leptospirosis, endorsed by the World Health Organization (WHO) since 1982, or other following modified versions are variable [7–10].

The present study aimed to detect clinical factors for predicting the diagnosis of leptospirosis in suspected cases, and to create a clinical prediction score that is practical and easy to use in general practice while awaiting confirmatory laboratory results.

Methods

Ethics statement

The study protocol was approved by the Institutional Review Board of Faculty of Medicine, Chulalongkorn University (IRB number 137/55), and the Institutional Review Board of Ministry of Public Health of Thailand (IRB number 005/2017). Participants consented for participation in the protocol.

Patients and study design

We performed a prospective multicenter study with a development and a validation cohort of patients presenting with clinical suspicion of leptospirosis as per the WHO clinical criteria [11]. Specific inclusion criteria included high fever (body temperature higher than 38˚C), severe myalgia, and history of exposure to reservoir animals or flood water. Exclusion criteria included patients who suffered from other known infectious diseases. The development cohort was conducted at 11 centers in 8 provinces around Thailand during 2012 to 2014. Blood and urine were serially collected on the first three days after enrollment and on day 7. The validation cohort was conducted at 4 centers from the Northeastern part of Thailand during 2015 to 2016. Blood and urine were collected on the first day after enrollment and on day 7. We applied the same inclusion and exclusion criteria to both the development and validation cohorts.

Sample collection

Twelve milliliters of blood and a 30 mL urine sample were taken from leptospirosis suspected patients on the first day of enrollment. Urine samples were poured into 50 ml conical centrifuge tubes. Both plasma and urine were centrifuged for 10 minutes at 1000g at 4˚C, and frozen at -20˚C until shipped to the central laboratory. Samples were then stored at -80˚C until analyzed.
Definitions

We used three standard techniques to confirm leptospirosis: microscopic agglutination test (MAT), direct culture, and PCR technique. Briefly, MAT was performed using the standard protocol from the WHO guideline [11]. A positive MAT was defined as a single serum titer of ≥ 1:400 or a 4-fold rise in pair serum. For direct culture of leptospires, one drop of whole blood was cultured in 4 mL liquid Ellinghausen–McCullough–Johnson–Harris at 29 °C for 2 weeks. Detection of leptospires was accomplished by direct observation using dark-field microscopy. For PCR technique, DNA was extracted from urine samples using a High Pure PCR Template Preparation kit (Roche Diagnostics, Germany). The two primers used for amplification of LipL 32 gene were as follows: 45F primers (5’ AAG CAT TAC CGC TTG TGG TG3’) and 287R primers (5’ CGA ACT CCC ATT TCAGCG AT 3’). PCR reactions of urine samples were performed in a final volume of 20 μL, corresponding to 2 μL of genomic DNA and 18 μL of reaction mix containing 25 mM of each dNTP, 0.1 μL of Taq DNA polymerase, 0.4 μL of each primer in 25 mM MgCl₂ and 10x KCl under 13.5 μL DW. The PCR program consisted of an initial cycle of 94 °C for 10 min; followed by 40 cycles of each 94 °C for 1 min, 55 °C for 1 min, and 72 °C for 1 min; and a final extension step at 72 °C for 7 min. PCR products were run on 1% agarose gel with ethidium bromide and photographed. We used the term "Leptospirosis suspected cases" for patients who were enrolled into the study, and "Leptospirosis confirmed cases (Leptospirosis)" if any one of the above tests was positive.

Statistical analyses

Statistical analyses were performed using SPSS software, version 17.0, with statistical significance set at \( p < 0.05 \). Comparisons between leptospirosis and non-leptospirosis groups were performed with Pearson’s Chi-Square asymptotic test or Fisher’s Exact test for categorical variables and using Student’s \( t \)-Test or Kruskal-Wallis one-way analysis of variance by ranks for continuous variables.

In a development cohort, we considered 14 clinical factors and conducted univariate and multivariable logistic regression to identify significant predictors of leptospirosis. In the multivariable models we looked at each clinical factor at a time and adjusted for age, gender, and fever day. Next, based on the adjusted models, we identified 6 clinical factors that were significant predictors of leptospirosis and, because of clinical importance, considered 2 additional factors that did not have statistical significance to use in developing a clinical score for leptospirosis. The likelihood ratio test, Hosmer-Lemeshow goodness of fit test, and Nagelkerke pseudo R-Square were used in selecting the two multivariable models that were the basis for developing our clinical score. Specifically, we used a model based on all 8 clinical factors (model 1), and a model based on the 6 significant factors plus one nonsignificant but clinically important factor (model 2). For each of the 2 models we created two prediction scores as follows: 1) a score based on the exponential equation \( 1/(1+e^{-Z}) \), where Z is the sum of all parameter estimates from the multivariable logistic regression given that a condition was present (original THAI-LEPTO); 2) a simplified score by adding the adjusted odds ratio values, rounded to the nearest 0.5, given that a condition was present (simplified THAI-LEPTO) [12]. We used receiver operating characteristic (ROC) curve analysis to evaluate the diagnostic ability of our scores. We compared the area under the curve (AUC), sensitivity, specificity, likelihood ratio, and post-test probability values to find the optimal cutoff values of the THAI-LEPTO scores. Furthermore, we evaluated our models at different days from fever onset.
Finally, we used a validation cohort to evaluate the accuracy of our methods. IgM rapid test performance statistics were used as a comparison group in both the development and validation cohorts.

**Results**

In the development cohort, we enrolled 221 leptospirosis suspected cases of which 211 were analyzed. Among those, 105 (50%) were leptospirosis confirmed cases and 106 (50%) were confirmed to not have leptospirosis (Fig 1A). In the validation cohort 96 leptospirosis suspected cases were enrolled but only 92 were analyzed. Of those, 69 (75%) were leptospirosis confirmed cases and 23 (25%) were confirmed to not have leptospirosis (Fig 1B). The three most common serovars in our pulled cohort were Shermani (55.3%), Australis (12.8%), and Sejroe (4.3%).

**Development cohort analysis**

For the development cohort, comparisons of clinical, laboratory and radiographic characteristics between leptospirosis and non-leptospirosis groups at the time of enrollment are shown in

---

![Flow chart](https://doi.org/10.1371/journal.pntd.0006319.g001)

**Fig 1.** Flow chart of subject disposition for the THAI-LEPTO score study in development cohort (A) and validation cohort comparing between THAI-LEPTO score and IgM rapid test (B). *Development cohort in 11 centers during 2012 to 2014. *Validation cohort in 4 centers during 2015 to 2016. *Simplified THAI-LEPTO score model II (7 variables) with cutoff value of 4 was used in the validation analysis.

https://doi.org/10.1371/journal.pntd.0006319.g001
Table 1. Leptospirosis patients had mean age of 42.8 years old, were predominantly male (81.9%), and worked as farmers (62.1%). There was no difference in body weight, occupation, comorbid conditions, and epidemiologic exposures (mostly flood exposure) between the leptospirosis and non-leptospirosis groups.

In logistic regression analysis adjusted for age, gender, day of fever, and one clinical factor at a time, we found that the leptospirosis group had more hypotension OR = 2.76 (95% CI 1.07–7.10), jaundice OR = 3.40 (95% CI 1.48–8.44), muscle pain OR = 2.12 (95% CI 1.06–4.26), acute kidney injury (AKI) OR = 2.90 (95% CI 1.31–6.15), low hemoglobin (Hb < 12 g/dL) OR = 3.48 (95% CI 1.72–7.04), and hypokalemia with hyponatremia (K < 3.5 mEq/L with Na < 135 mEq/L) OR = 3.56 (95% CI 1.17–10.84) than the non-leptospirosis group (Fig 2).

The abovementioned clinical factors along with neutrophilia and pulmonary opacity were used in the development of the THAI-LEPTO score. Model 1 contains all 8 variables. Model 2 omits pulmonary opacity containing only 7 variables. Table 2 contains the two models along with: 1) parameter estimates to be used in the original score; 2) rounded adjusted odds ratios to be used in the simplified score. Model 2 had a percentage of correct responses (that is, the overall percentage of correct positive and negative responses) of 73.0% with a Hosmer-Lemeshow p-value of 0.33 and a Nagelkerke R square of 0.28.

The AUC were 0.78 (95%CI 0.67–0.88) for original THAI-LEPTO score model 1 at cutoff of 0.47, 0.78 (95%CI 0.68–0.89) for simplified score model 1 at cutoff of 5, and 0.77 (95%CI 0.69–0.85) simplified score model 2 at cutoff of 4 (Fig 3A). The AUC (95% CI) for model 2 stratified by days from fever onset were: 0.70 (0.46, 0.39) for < 3 days; 0.82 (0.67, 0.97) for 3–4 days; and 0.80 (0.58, 1.00) for > 4 days (Fig 3B).

Sensitivity, specificity, positive likelihood ratio and post-test probability at different cutoff values of the scores from the simplified models 1 and 2 compared with the IgM rapid test are shown in Table 3.

Validation cohort analysis

For the validation cohort, the AUC of the simplified THAI-LEPTO score model 2 at cutoff of 4 and IgM rapid test were 0.78 (95%CI 0.68–0.89) and 0.58 (95%CI 0.42–0.74) respectively (Fig 4). The performance of the simplified score model 2 at a cutoff value of 4 versus that of the IgM rapid test was: 73.5 vs. 50.0 for sensitivity; 73.7 vs. 66.7 for specificity; 87.8 vs. 85.3 for positive predictive value; 58.3 versus 25.6 for negative predictive value; 2.79 vs. 1.5 for positive likelihood ratio; and 0.74 vs. 0.57 for positive post-test probability (Table 4).

Discussion

In summary, in patients presenting with clinical suspicion of leptospirosis we found that several clinical and laboratory parameters present on admission are associated with leptospirosis. Early hypotension, jaundice, muscle pain, AKI, low hemoglobin, and hypokalemia combined with hyponatremia were all associated with leptospirosis (Table 1). Additionally, neutrophilia and pulmonary opacity, although not significant predictors of leptospirosis in either univariate or multivariable analyses (Fig 2), when added to the multivariable models increased the AUC thus improving their predicting ability and providing a more accurate THAI-LEPTO score. Interestingly, THAI-LEPTO score had the highest discriminatory power (AUC 0.82, 95% CI 0.67–0.97) on days 3 or 4 after onset of fever (Fig 3B). Thus, THAI-LEPTO score is a useful tool in the early diagnosis of leptospirosis when rapid-serologic tests are not helpful.

Early diagnosis of leptospirosis is essential in improving outcomes. However, differentiating leptospirosis from other tropical infectious diseases such as dengue infection, or scrub typhus which share common clinical presentations is challenging to physicians. Moreover,
| Clinical characteristics | Leptospirosis (n = 105) | Non-Leptospirosis (n = 106) | P-value  |
|--------------------------|-------------------------|-----------------------------|----------|
| Age, years, (SD)         | 42.8 (15.2)             | 43.2 (16.1)                 | 0.86     |
| Male gender, n (%)       | 86 (81.9)               | 80 (75.5)                   | 0.25     |
| Body weight, kg, (SD)    | 58.9 (12.5)             | 61.0 (10.2)                 | 0.25     |
| Height, cm., (SD)        | 164.6 (7.5)             | 165.3 (9.2)                 | 0.62     |
| Body Mass Index, kg/m² (SD) | 21.7 (4.1)           | 22.4 (3.2)                  | 0.26     |
| Occupation (n = 100)     |                         |                             | 0.21     |
| Farmer, n (%)            | 54 (62.1)               | 59 (59.0)                   |          |
| Worker, n (%)            | 21 (24.1)               | 24 (24.0)                   |          |
| Business, n (%)          | 1 (1.1)                 | 4 (4.0)                     |          |
| Public servants, n (%)   | 1 (1.1)                 | 0                            |          |
| Housewife/householder, n (%) | 3 (3.4)            | 0                            |          |
| Student, n (%)           | 3 (3.4)                 | 10 (10.0)                   |          |
| Unemployment, n (%)      | 3 (3.4)                 | 2 (2.0)                     |          |
| Monk, n (%)              | 1 (1.1)                 | 1 (1.0)                     |          |
| Currently tobacco use, n (%) | 42/98 (42.9)         | 24/92 (26.1)                 | 0.015    |
| Alcoholism, n (%)        | 6/103 (5.8)             | 3/102 (2.9)                 | 0.50     |
| Co-morbidity disease     |                         |                             |          |
| Diabetes, n (%)          | 5/103 (4.9)             | 3/102 (2.9)                 | 0.72     |
| Hypertension, n (%)      | 8/103 (7.8)             | 2/102 (2.0)                 | 0.10     |
| Dyspemia, n (%)          | 4/104 (3.8)             | 3/102 (2.9)                 | >0.99    |
| Malignancy, n (%)        | 1/103 (1.0)             | 0/102 (0.0)                 | >0.99    |
| Anemia, n (%)            | 2/102 (2.0)             | 1/101 (1.0)                 | >0.99    |
| Gout, n (%)              | 2/102 (2.0)             | 1/101 (1.0)                 | >0.99    |
| Asthma/COPD, n (%)       | 3/103 (2.9)             | 1/102 (1.0)                 | 0.62     |
| CKD, n (%)               | 2/102 (2.0)             | 1/101 (1.0)                 | >0.99    |
| Chronic liver disease, n (%) | 4/103 (3.9)       | 1/102 (1.0)                 | 0.37     |
| Exposure                 |                         |                             |          |
| Flood, n (%)             | 69/104 (66.3)           | 65/99 (65.7)                 | 0.92     |
| Animal, n (%)            | 11/104 (10.6)           | 8/99 (8.1)                  | 0.54     |
| Symptoms and signs       |                         |                             |          |
| Days of fever, day (Q1,Q3) | 4 (3, 5)              | 3 (2, 4.25)                 | 0.034    |
| Body temperature, °C (SD) | 38.1 (1.1)             | 38.4 (1.1)                  | 0.039    |
| Jaundice, n (%)          | 34/104 (32.7)           | 14/102 (13.7)               | 0.001    |
| Nausea, n (%)            | 36/104 (34.6)           | 41/102 (40.2)               | 0.41     |
| Vomiting, n (%)          | 31/104 (29.8)           | 25/102 (24.5)               | 0.39     |
| Headache, n (%)          | 65/104 (62.5)           | 65/102 (63.7)               | 0.86     |
| Photophobia, n (%)       | 6/104 (5.8)             | 3/102 (2.9)                 | 0.50     |
| Malaise and fatigue, n (%) | 78/104 (75.0)       | 77/102 (73.5)               | 0.94     |
| Alteration of consciousness, n (%) | 3/104 (2.9)    | 3/102 (2.9)                 | >0.99    |
| Skin lesion, n(%)        | 3/104 (4.8)             | 3/102 (2.9)                 | 0.72     |
| Abdominal pain, n (%)    | 22/104 (21.2)           | 10/102 (9.8)                | 0.025    |
| Gross hematuria, n (%)   | 3/104 (2.9)             | 1/102 (1.0)                 | 0.62     |
| Dysuria, n (%)           | 2/104 (1.9)             | 5/102 (4.9)                 | 0.28     |
| Muscle pain, n (%)       | 37/104 (35.6)           | 20/102 (19.6)               | 0.01     |
| Convulsion, n (%)        | 1/104 (1.0)             | 1/102 (1.0)                 | >0.99    |
| Dypsnea, n (%)           | 14/104 (13.5)           | 7/102 (6.9)                 | 0.12     |

(Continued)
### Table 1. (Continued)

| Clinical characteristics                  | Leptospirosis (n = 105) | Non-Leptospirosis (n = 106) | P-value |
|-------------------------------------------|-------------------------|-----------------------------|---------|
| Cough, n (%)                              | 25/104 (24.0)           | 19/102 (18.6)               | 0.34    |
| Hemoptysis, n (%)                         | 4/104 (3.8)             | 3/102 (2.9)                 | 0.99    |
| Hypotension, n (%)                        | 21/104 (20.2)           | 7/102 (6.9)                 | 0.005*  |
| Diarrhea, n (%)                           | 2 (1.9)                 | 1 (0.9)                     | 0.62    |
| Subconjunctival suffusion, n (%)          | 3 (2.9)                 | 1 (0.9)                     | 0.37    |
| Sore throat, n (%)                        | 3 (2.9)                 | 4 (3.8)                     | >0.99   |
| Systolic Blood Pressure, mmHg (Q1,Q3)     | 110 (100, 121)          | 114 (100, 122)              | 0.12    |
| Diastolic Blood Pressure, mmHg (Q1,Q3)    | 69.5 (60, 80)           | 70 (60, 80)                 | 0.08    |
| Laboratory values                         |                         |                             |         |
| Hb, g/dL, SD                              | 11.5± 2.4               | 13.2± 2.4                   | <0.001* |
| WBC x10³/μL (Q1,Q3)                       | 9.1 (6.6, 13.7)         | 8.5 (5.5, 11.65)            | 0.18    |
| PMN, % (Q1,Q3)                            | 78.0 (70.0, 87.0)       | 74.65 (65.0, 84.8)          | 0.08    |
| Platelet x10³/μL (Q1,Q3)                  | 132 (53.25, 204.25)     | 156 (112, 246.5)            | 0.008*  |
| Urine sp.gr (Q1,Q3)                       | 1.015 (1.010, 1.025)    | 1.020 (1.015, 1.025)        | 0.046   |
| Urine protein                              |                         |                             | 0.23*   |
| Negative n(%), Trace n(%), 1+, n(%), 2+, n(%), 3+, n(%), > 3+, n(%) | | | |
| Urine RBC/HPF (Q1,Q3)                     | 1 (0.2, 25)             | 1 (0.2)                     | 0.33    |
| Urine WBC/HPF (Q1,Q3)                     | 2 (1.7, 5)              | 1 (1.3)                     | 0.039*  |
| Urine RBC cast (Q1,Q3)                    | 0 (0, 0)                | 0 (0, 0)                    | 0.25    |
| Urine WBC cast (Q1,Q3)                    | 0 (0, 0)                | 0 (0, 0)                    | 0.40    |
| Urine granular cast (Q1,Q3)               | 0 (0, 0)                | 0 (0, 0)                    | 0.58    |
| Total Bilirubin, μmol/L (Q1,Q3)           | 34.88 (14.11, 127.82)   | 23.43 (11.97, 63.27)        | 0.06    |
| Direct Bilirubin, μmol/L (Q1,Q3)          | 23.00 (5.13, 84.65)     | 8.64 (5.10, 32.92)          | 0.11    |
| Aspartate aminotransferase, μkat/L (Q1,Q3)| 0.75 (0.43, 1.64)       | 0.95 (0.53, 2.61)           | 0.14    |
| Alanine aminotransferase, μkat/L (Q1,Q3)  | 0.74 (0.48, 1.59)       | 1.01 (0.5, 1.91)            | 0.26    |
| Serum Sodium, mmol/L (Q1,Q3)              | 135.0 (131.3, 138.0)    | 136.5 (131.8, 138.8)        | 0.54    |
| Serum Potassium, mmol/L (Q1,Q3)           | 3.52 (3.29, 3.90)       | 3.70 (3.4F0, 4.06)          | 0.10    |
| Serum bicarbonate, mmol/L (Q1,Q3)         | 21.4 (18.0, 25.3)       | 22.8 (18.0, 25.0)           | 0.66    |
| Serum creatinine, μmol/L (Q1,Q3)          | 104.34 (77.81, 307.7)   | 83.11 (67.2, 107.87)        | 0.001*  |
| AKI, on admission, n (%)                  | 37/104 (35.6)           | 17/104 (16.3)               | 0.002   |
| AKI, all cases, n (%)                     | 40 (38.1)               | 20 (18.9)                   | 0.002   |
| IgG rapid test², positive, n (%)          | 2/50 (4.0)              | 5/48 (10.4)                 | 0.26    |
| IgM rapid test², positive, n (%)          | 25/64 (39.1)            | 20/62 (32.3)                | 0.43    |
| Chest X-ray findings (n = 53)             |                         |                             | 0.18    |
| Normal, n (%)                             | 40 (75.5)               | 52 (86.7)                   | 0.13    |

(Continued)
current diagnostic tests including MAT, direct culture, and the IgM rapid test remain less sensitive and are of little help in decision-making during the early phase of infection [13]. Most of the time physicians use clinical manifestations and initial laboratory investigations to make a diagnosis and recommend treatment. THAI-LEPTO score should help physicians with limited access to diagnostic tools and varied clinical experience in diagnosing leptospirosis early. Even though some studies have well established clinical manifestations of leptospirosis [14–16] and another has recently proposed a diagnostic scoring model for leptospirosis [17]. To our knowledge, this is the first prospective study that develops and validates a score based on clinical and basic laboratory and radiographic characteristics present at the bedside to aid clinicians in the early diagnosis of leptospirosis.

In clinical practice the IgM rapid test is used for diagnosing leptospirosis. We thus compared the accuracy of the THAI-LEPTO score with that of the IgM rapid test applied to the validation cohort. Our score outperformed the IgM rapid test on all metrics used confirming its usefulness (Table 4). Clinical diagnostic scoring models have been developed and used in many countries because serologic tests are of less help in the early phase of infection. However, the accuracy of the previous models is variable. The performance of the simplified THAI-LEPTO score model 2 at a cutoff value of 4 is compared with other scoring models in Table 5. Although each model may have internal validity, the metrics reported in one study may not be generalizable outside the original population. Thus, comparisons between studies should be made while keeping study similarities in mind. With this in mind, between our scoring system and the recently reported scoring system from Sri Lanka [17], THAI-LEPTO score has higher specificity and positive likelihood ratio while Sri Lanka has better sensitivity and negative likelihood ratio.

THAI-LEPTO score model 2 can be applied at the point of care as shown in S1 Fig. When a patient is clinically suspected of leptospirosis (WHO clinical description with epidemiologic exposure) they can be tested by the simplified score at the time of admission. If the patient’s score equals 4 or more, physicians can make a presumptive diagnosis of leptospirosis with a positive post-test probability of 0.74. However, other specific diseases such as hepatobiliary

| Table 1. (Continued) |
|----------------------|
| **Clinical characteristics** | **Leptospirosis** | **Non-Leptospirosis** | **P-value** |
| Pulmonary opacities, n (%) | 11 (20.8) | 5 (8.3) | 0.059 |
| Pulmonary vascular congestion, n (%) | 2 (3.8) | 3 (5.0) | >0.99c |
| Electrocardiographic findings | | | 0.08c |
| Normal, n (%) | 30 (28.6) | 46 (43.4) | 0.025 |
| Sinus tachycardia, n (%) | 4 (3.8) | 1 (0.9) | 0.21c |
| ST-T abnormalities, n (%) | 2 (1.9) | 0 (0.0) | 0.25c |
| Ectopic beats, n (%) | 0 (0.0) | 1 (0.9) | >0.99c |
| Tachyarrhythmia, n (%) | 1 (1.0) | 2 (1.9) | >0.99c |
| Bradyarrhythmia, n (%) | 1 (1.0) | 1 (0.9) | >0.99c |

a Statistical significance
Abbreviations: AKI; acute kidney injury, CKD; chronic kidney disease, PMN; polymorphonuclear leucocyte, COPD; chronic obstructive pulmonary disease
b AKI, on admission, including AKI which presented on day of admission
c AKI, all cases, including AKI which presented on day of admission and during hospital stay
d P-value from Fisher’s exact test

https://doi.org/10.1371/journal.pntd.0006319.t001
tract infection, bacterial sepsis, and malaria must be ruled out before making the initial diagnosis of leptospirosis.

THAI-LEPTO score is potentially easy to apply in clinical practice since it is derived from clinical manifestations and basic investigations. The parameters considered should be available in most hospitals even in resource-limited countries. However, THAI-LEPTO score may be less accurate (i.e. less sensitive and/or less specific) in detecting mild forms of leptospirosis which have non-specific clinical manifestations.

Interestingly, evidence of clinical and pathophysiological correlation between each predictor and leptospirosis has been documented. Hypotension, an early presenting sign of leptospirosis[18], may be the result of several factors, including initial systemic vasodilatation and increased vascular permeability secondary to cytokines and vasoactive mediators[19, 20], and hypovolemia from decreased fluid intake and increased insensible loss due to fever[21]. Muscle pain and tenderness mainly involve the calf and lumbar areas and there has been some evidence that muscle injury might be caused directly by leptospires during the early phase of

| Parameter                          | OR (95% CI)  | P-value |
|------------------------------------|--------------|---------|
| Hypotension                        | 3.43 (1.39-8.49) | 0.008   |
| Jaundice                           | 3.05 (1.52-6.13) | 0.002   |
| Muscle pain                        | 2.26 (1.20-4.26) | 0.011   |
| AKI on admission                   | 2.83 (1.47-5.45) | 0.002   |
| Hb < 12                            | 3.39 (1.84-6.23) | < 0.001 |
| K < 3.5                            | 1.81 (0.94-3.49) | 0.074   |
| Na < 135                           | 1.22 (0.65-2.28) | 0.535   |
| K < 3.5 & Na < 135                 | 3.18 (1.18-8.55) | 0.022   |
| Platelet < 150,000                 | 1.69 (0.96-2.97) | 0.071   |
| WBC <10,000                        | 1.16 (0.66-2.05) | 0.614   |
| PMN ≥ 80 %                         | 1.18 (0.65-2.14) | 0.580   |
| PMN ≥ 80 % & WBC < 10,000          | 1.16 (0.52-2.60) | 0.711   |
| Pulmonary vascular congestion     | 0.75 (0.12-4.64) | 0.752   |
| Pulmonary opacities                | 2.88 (0.93-8.93) | 0.067   |
| IgM rapid test                     | 1.35 (0.65-2.80) | 0.426   |

Fig 2. Forest plots of unadjusted (A) and adjusted (B) odds ratio in clinical prediction of leptospirosis, comparing with IgM rapid test in development cohort.

https://doi.org/10.1371/journal.pntd.0006319.g002
infection [22] which could explain why calf pain might occur even before fever or other systemic symptoms. Jaundice, one of the most clinically recognizable features of leptospirosis, also known as leptospirosis icterohemorrhagica or Weil’s disease, results from cholestasis rather than hepatocellular damage as implied by a characteristic disproportion between the slight elevations in transaminase despite markedly high bilirubin levels.

Renal involvement is also notable in leptospirosis. According to Sitprija et al., the pathogenesis of renal complications is the result of direct invasion of leptospires, hemodynamic changes, and inflammation [23]. In severe cases of leptospirosis, non-specific inflammatory factors including hemolysis, myonecrosis, intravascular coagulation, free radicals, hyperbilirubinemia and increased blood viscosity additionally contribute to impaired renal function [19]. The renal pathology of AKI from leptospirosis has more extensive damage than other diseases, especially at proximal convoluted tubules [24].

Electrolyte disturbances are common features of tropical diseases. Hyponatremia in leptospirosis is attributed to several causes, including urinary sodium loss, cellular influx of sodium due to decreased Na\(^+\) / K\(^+\)-APTase activity, increased level of ADH, and resetting of osmoreceptors [25]. Hypokalemia and polyuria are notable in leptospirosis and can be explained by a decrease in the expression of sodium/hydrogen exchanger isoform 3 (NHE 3), aquaporin 1, and \(\alpha\)-Na\(^+\)/K\(^+\)-ATPase in proximal convoluted tubule cells [24]. On the other hand, aquaporin 2 expression in the collecting tubules is enhanced in leptospirosis kidneys compared to non-leptospirosis kidneys [24]. Therefore, although hyponatremia and hypokalemia can separately

---

**Table 2. Creating the THAI-LEPTO score of development cohort with multivariable regression-based method (n = 211).**

| Predictors                  | Model I (8 variables) |           |         | Model II (7 variables) |           |         |
|-----------------------------|-----------------------|-----------|---------|------------------------|-----------|---------|
|                             | Parameter estimates\(^a\) | Adjusted odds ratio\(^b\) | Simplified score\(^c\) | Parameter estimates\(^a\) | Adjusted odds ratio\(^b\) | Simplified Score\(^c\) |
| Hypotension                 | 1.301                 | 3.674     | 3.5     | 1.030                  | 2.802     | 3       |
| Jaundice                    | 0.302                 | 1.352     | 1.5     | 0.813                  | 2.256     | 2       |
| Muscle Pain                 | 0.791                 | 2.205     | 2.0     | 0.614                  | 1.847     | 2       |
| AKI                         | 0.387                 | 1.473     | 1.5     | 0.416                  | 1.516     | 1.5     |
| Hb < 12 g/dL                | 1.063                 | 2.896     | 3.0     | 1.028                  | 2.796     | 3       |
| K < 3.5 & Na < 135          | 1.440                 | 4.221     | 4.0     | 1.126                  | 3.082     | 3       |
| PMNs ≥ 80% & WBC < 10,000/\(\mu\)L \(^d\) | 0.617               | 1.853     | 2.0     | 0.097                  | 1.102     | 1       |
| Pulmonary opacity\(^d\)     | 0.085                 | 1.089     | 1.0     | -                      | -         | -       |
| Constant                    | -1.852                | 0.157     | -       | -1.376                 | 0.253     | -       |

Abbreviations: AKI; acute kidney injury, Hb; hemoglobin, Na; sodium, K; potassium, PMN; polymorphonuclear leucocyte; WBC; white blood cell

\(^a\)Parameter estimates (commonly known as unstandardized coefficients in multivariable regression model) for original THAI-LEPTO score equation.

Original THAI-LEPTO score (model I) equation is \(\frac{Z}{e^{Z}}\), \(Z = -1.852\) (in every case) +1.301 (if has “Clinical Hypotension”) + 0.302 (if has “Clinical Jaundice”) + 0.791 (if has “Muscle pain”) + 0.387 (if has “AKI”) + 1.063 (if has “Hb < 12”) + 1.440 (if has “K < 3.5 & Na < 135”) + 0.617 (if has “PMNs ≥ 80% & WBC < 10,000”) + 0.085 (if has “Pulmonary opacity”)

\((Z\ value\ was\ derived\ from\ summation\ of\ B\ values\ of\ regression\ coefficients\ multiply\ with\ each\ factor\ value\ (has\ the\ condition = 1,\ not\ has\ the\ condition = 0)\ in\ binary\ logistic\ regression\ models;\ -1.852\ is\ the\ constant\ in\ equation;\ e\ value\ is\ 2.71828,\ as\ the\ mathematic\ constant.)\)

\(^b\)Adjusted odds ratio for covariates in multivariable regression analysis

\(^c\)Simplified score closed to nearest integer of the adjusted odds ratio for simplified THAI-LEPTO score equation.

Simplified THAI-LEPTO score is the sum of scores of the conditions; +3.5 (if has “Clinical Hypotension”) + 1.5 (if has “Clinical Jaundice”) + 2.0 (if has “Muscle pain”) + 1.5 (if has “AKI”) + 3 (if has “Hb < 12”) + 4 (if has “K < 3.5 & Na < 135”) + 2 (if has “PMNs ≥ 80% & WBC < 10,000”) + 1 (if has “Pulmonary opacity”), as show in S1 Fig

\(^d\)Two predictors; pulmonary opacity and PMNs ≥ 80% & WBC < 10,000 were not obviously significant predictors in primarily uni-variable and multi-variable analysis (Fig 2), but these predictors could increase area under the ROC curve in analysis.

https://doi.org/10.1371/journal.pntd.0006319.t002
occur in many tropical diseases \([25, 26]\) hyponatremia together with hypokalemia was characteristically found in leptospirosis (Fig 2).

Pulmonary involvement has been reported in 20–70% of leptospirosis patients. Chest radiographs of leptospirosis are characterized primarily by diffuse small opacities that are disseminated or coalesced into larger areas of consolidation \([27]\). Despite the presence of clinical symptoms, pulmonary hemorrhage may also be concealed with few or no chest radiographic abnormalities \([28]\). Andrade et al. postulated that leptospirosis infection could cause a decrease in epithelial sodium channel (ENaC) and an increase in Na-K-Cl cotransporter (NKCCl) expression that dissipate the osmotic gradient of Na between the alveolar lumen and the interstitium. This leads to increased pulmonary permeability such as that observed in acute respiratory distress syndrome (ARDS) \([29]\).

Fig 3. The area under the receiver operating characteristic (ROC) curve for predicting leptospirosis in each model of THAI-LEPTO scores, comparing with IgM rapid test (A) and according to fever days of simplified model (B) in development cohort study. AUC, area under ROC curve

https://doi.org/10.1371/journal.pntd.0006319.g003

### Table 3. THAI-LEPTO score of the development cohort at the best cutoff value to predict leptospirosis in suspected cases, comparing with IgM rapid test (n = 211).

| Parameter/Models                  | Cutoff value | Sensitivity (%) | Specificity (%) | Positive Likelihood ratio | Positive, Post-Test Probability* |
|-----------------------------------|--------------|-----------------|-----------------|--------------------------|----------------------------------|
| THAI-LEPTO score 8 variables      | 4.5          | 79.4            | 65.8            | 2.321                    | 0.699                            |
| (Simplified model I)              | 5            | 79.4            | 71.1            | 2.743                    | 0.733                            |
|                                  | 5.5          | 70.6            | 76.3            | 2.980                    | 0.749                            |
| THAI-LEPTO score 7 variables      | 3.5          | 74.6            | 68.6            | 2.37                     | 0.703                            |
| (Simplified model II)             | 4.0          | 71.6            | 74.3            | 2.786                    | 0.736                            |
|                                  | 4.5          | 67.2            | 75.7            | 2.766                    | 0.734                            |
| IgM rapid test\(^b\)             | 0.519        | 39.1            | 67.7            | 1.21                     | 0.548                            |

*In condition with pre-test probability is 0.5

\(^b\)Rapid test with lateral flow immunochromatographic assay, read by naked eye

https://doi.org/10.1371/journal.pntd.0006319.t003
Low hemoglobin, a common finding in leptospirosis that has not been emphasized in literature, is caused by several factors including blood loss and hemolysis [30]. Although the exact mechanism of abnormal bleeding is not currently well understood, several facilitating factors may be thrombocytopenia, capillary endothelial damage, and coagulation defects resulting from hepatic dysfunction, consumptive coagulopathy and disseminated intravascular coagulation [31].

![ROC curve for predicting leptospirosis](https://doi.org/10.1371/journal.pntd.0006319.g004)

**Table 4.** Accuracy of the simplified THAI-LEPTO score comparing with IgM rapid test in validation cohort analysis (n = 92).

| Tools                | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | Positive LR | Negative LR | Positive posttest probability<sup>a</sup> | Negative posttest probability<sup>a</sup> |
|----------------------|-----------------|-----------------|---------|---------|-------------|------------|------------------------------------------|------------------------------------------|
| THAI-LEPTO score<sup>b</sup> | 73.5            | 73.7            | 87.8    | 58.3    | 2.79        | 0.36       | 0.74                                     | 0.26                                     |
| IgM rapid test<sup>b</sup> | 50              | 66.7            | 85.3    | 25.6    | 1.5         | 0.75       | 0.6                                      | 0.43                                     |

Abbreviations: PPV; positive predictive value, NPV; negative predictive value, LR; likelihood ratio

<sup>a</sup>Simplified THAI-LEPTO Score Model II (7 variables) at cutoff value = 4

<sup>b</sup>Rapid Diagnosis Test with lateral flow immunochromatographic assay, read by naked eye

<sup>c</sup>In condition with pre-test probability is 0.5

[https://doi.org/10.1371/journal.pntd.0006319.t004](https://doi.org/10.1371/journal.pntd.0006319.t004)
This was a prospective, multicenter study that used 3 standard confirmatory tests for leptospirosis: MAT, direct culture, and PCR. Additionally, the study had both a development and a validation cohort. However, our study has some limitations. First, the patients enrolled in the study were from an endemic area of leptospirosis which may limit the generalizability of the THAI-LEPTO score in non-endemic areas. Secondly, the score should be applied only after excluding other known infectious diseases, as the study was only conducted in leptospirosis suspected cases without other infectious diseases. Thirdly, most of the enrolled cases had severe clinical manifestations upon admission limiting the applicability of the score to severe leptospirosis suspected cases.

To conclude, THAI-LEPTO score is a newly developed diagnostic tool for early presumptive diagnosis of leptospirosis in patients presenting with severe clinical suspicion of the disease. Each predictor used in the score has been supported by evidence of clinical and pathophysiological correlation. However, an additional large validation study may be needed to evaluate the usefulness in general practice and in patients from non-endemic areas.

### Supporting information

**S1 Fig. The proposed diagram of simplified THAI-LEPTO score (8 variables) in clinical practice at the point of care.** aClinical criteria of leptospirosis according to WHO clinical description as the usual presentation is an acute febrile illness with headache, myalgia (particularly calf muscle) and prostration associated with any of the following symptoms/signs: conjunctival suffusion, anuria or oliguria, jaundice, cough; hemoptysis and breathlessness, hemorrhages (from the intestines; lung bleeding is notorious in some areas), meningeal irritation, Cardiac arrhythmia of failure, skin rash bFor cutoff value of 5; the Sensitivity,
Specificity, Positive likelihood ratio and Post-Test Probability are 0.794, 0.711, 2.740, and 0.733, respectively. For in detail of other cutoff values of simplified and original THAI-LEPTO Score models see Table 4. Other specific diseases such as hepatobiliary tract infection, bacterial sepsis, and malaria must be ruled out before making a presumptive diagnosis of leptospirosis. Definition of each factor: “Clinical Jaundice”; yellowish pigmentation of the skin, the sclera, and other mucous membranes, “Clinical Hypotension”; mean arterial pressure lower than 70 mm Hg or symptomatic low blood pressure that needed volume resuscitation or vasoressor, "Hb < 12"; hemoglobin < 12 g/dL, "AKI"; according to KDIGO criteria for acute kidney injury as increase in serum creatinine by \( \geq 0.3 \text{ mg/dL} \) (\( \geq 26.5 \, \mu \text{mol/L} \)) within 48 hours; or increase in serum creatinine to \( \geq 1.5 \) times baseline, which is known or presumed to have occurred within the prior seven days; or urine volume < 0.5 mL/kg/h for six hours, “Muscle pain”; non-traumatic-sore aching muscles that are commonly involve the calves and lower back, "K < 3.5 & Na < 135"; Potassium < 3.5 mEq/L combined with Sodium < 135 mEq/L, “PMNs \( \geq 80 \) & WBC < 10,000 cells/µL”; polymorphonuclear leucocytes \( \geq 80\% \) combined with white blood cells count < 10,000 /µL in a complete blood counts (CBC) test, “Pulmonary opacity”; on a chest X-ray lung abnormalities with increased density in any pattern such as consolidation, interstitial, or nodular pattern, that they may consist of nonspecific, diffuse, small opacities, which may be disseminated or coalesce in to larger area of consolidation such as in pulmonary edema, ARDS or lung hemorrhage.

Acknowledgments

Members of Thai Lepto-AKI study group include:

Nattachai Srisawat, M.D.(Lead author), Kearkiat Praditpornsilpa, M.D., Sadudee Peerapornratana, M.D., Passisd Loahaveerat, M.D., Nattachai Suwachittanont, M.D., Thaksa-on Wirotwan M.D., Chayanat Phonork, M.S., Sarinya Kumpunya, B.A., Khajohn Tiranathanagul, M.D., Somchai Eiam-ong, M.D., and Kriang Tungsanga, M.D., Natavudh Townamchai, M.D., from Division of Nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, and King Chulalongkorn Memorial Hospital, Bangkok, Thailand,

Kanitha Patarakul, M.D., Chintana Chirathaworn, Ph.D. from Department of Microbiology and Immunology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand;
Malee Techarorrung, M.D from Prapokklao hospital, Chantaburi, Thailand;
Tinnapop Daraswong, M.D. from Krasang hospital, Buriram, Thailand;
Theerapon Sukmark, M.D. from Thungsong hospital, Nakhon Si Thammarat, Thailand;
Kamol Khositrangsikun, M.D. from Maharaj Nakhon Si Thammarat hospital, Nakhon Si Thammarat, Thailand;
Apinya Fakhthongyoo, M.D. from Uttaradit hospital, Uttaradit, Thailand;
Petchdee Oranrigsupak, M.D. from Nan hospital, Nan, Thailand;
Laksamon Praderm, M.D. from Roiet hospital, Roiet, Thailand;
Ummarit Suwattanasilpa, M.D. from Mahasarakarn hospital, Mahasarakarn, Thailand;
Visith Sitprija, M.D. from Queen Saovabha Memorial Institute, Thai Red Cross, Thailand;
John A. Kellum, M.D. from The CRISMA Center, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, United States.

Author Contributions

Conceptualization: Theerapon Sukmark, Kriang Tungsanga, Nattachai Srisawat.

Data curation: Theerapon Sukmark.
Formal analysis: Theerapon Sukmark, Nattachai Srisawat.

Funding acquisition: Nattachai Srisawat.

Investigation: Theerapon Sukmark, Sadudee Peerapornratana, Nattachai Srisawat.

Methodology: Theerapon Sukmark, Nattachai Srisawat.

Project administration: Theerapon Sukmark, Nuttha Lumlertgul, Visith Sitprija, Nattachai Srisawat.

Resources: Theerapon Sukmark, Kamol Khositrangsikun, Nattachai Srisawat.

Software: Theerapon Sukmark.

Supervision: Nattachai Srisawat.

Validation: Theerapon Sukmark, Nattachai Srisawat.

Visualization: Theerapon Sukmark.

Writing – original draft: Theerapon Sukmark.

Writing – review & editing: Theerapon Sukmark, Nattachai Srisawat.

References

1. Thailand National Disease Surveillance (Report 506) [Internet]. Department of Disease Control, Ministry of Public Health, Thailand. 2017 [cited July 17, 2017].

2. Picardeau M, Bertheart E, Jancloes M, Skouloudis AN, Durski K, Hartskeerl RA. Rapid tests for diagnosis of leptospirosis: current tools and emerging technologies. Diagn Microbiol Infect Dis. Jan; 78(1):1–8. https://doi.org/10.1016/j.diagmicrobio.2013.09.012 PMID: 24207075. Epub 2013/11/12. eng.

3. Tanganuchitcharnchai A, Smythe L, Dohnt M, Hartskeerl R, Vongsouvath M, Davong V, et al. Evaluation of the Standard Diagnostics Leptospira IgM ELISA for diagnosis of acute leptospirosis in Lao PDR. Trans R Soc Trop Med Hyg. Sep; 106(9):563–6. https://doi.org/10.1016/j.trstmh.2012.06.002 PMID: 22818757. Epub 2012/07/24. eng.

4. Desakorn V, Wuthiekanun V, Thanachartwet V, Sahassananda D, Chierakul W, Aipi wattanaporn A, et al. Accuracy of a commercial IgM ELISA for the diagnosis of human leptospirosis in Thailand. Am J Trop Med Hyg. Mar; 86(3):524–7. https://doi.org/10.4269/ajtmh.2012.11-0423 PMID: 22403329. Epub 2012/03/10. eng.

5. Goris MG, Leeflang MM, Loden M, Wagenaar JF, Klatser PR, Hartskeerl RA, et al. Prospective evaluation of three rapid diagnostic tests for diagnosis of human leptospirosis. PLoS Negl Trop Dis. 7(7): e2290. https://doi.org/10.1371/journal.pntd.0002290 PMID: 23875034. Epub 2013/07/23. eng.

6. Faine S. Guideline for leptospirosis control. World Health Organization Geneva. Offset publication. 1982; 67:161.

7. Chaifou W. How to diagnose leptospirosis. Weekly Epidemiological Surveillance Report of Thailand. 2010; 41(46):733–6. July, 20. Thai.

8. Jose LR, Sumana M. Utilization of Faine’s Criteria for the Diagnosis of Leptospirosis.

9. Bandara K, Weerasekera MM, Gunasekara C, Ranasinghe N, Marasinghe C, Fernando N. Utility of modified Faine’s criteria in diagnosis of leptospirosis. BMC Infectious Diseases. 2016; 16(1):446. https://doi.org/10.1186/s12879-016-1791-9 PMID: 27554098

10. Bhatia M, Umapathy B, Navaneeth B. Evaluation Of Diagnostic Utility Of Modified Faine’s Criteria In Leptospirosis-Experience From A Tertiary Care Hospital. 2015.

11. World Health Organization. Human leptospirosis: guidance for diagnosis, surveillance and control. 2003. World Health Organization: Geneva, Switzerland.

12. DiStefano C, Zhu M, Mindrila D. Understanding and using factor scores: Considerations for the applied researcher. Practical Assessment, Research & Evaluation. 2009; 14(20):1–11.

13. Schreier S, Doungchawee G, Chadthiti S, Triampo D, Triampo W. Leptospirosis: current situation and trends of specific laboratory tests. Expert Rev Clin Immunol. Mar; 9(3):263–80. https://doi.org/10.1586/eci.12.110 PMID: 23445200. Epub 2013/03/01. eng.
14. Katz AR, Ansdell VE, Effler PV, Middleton CR, Sasaki DM. Assessment of the clinical presentation and treatment of 353 cases of laboratory-confirmed leptospirosis in Hawaii, 1974–1998. Clin Infect Dis. 2001 Dec 1; 33(11):1834–41. https://doi.org/10.1086/324084 PMID: 11692294. Epub 2001/11/03. eng.

15. Yang HY, Hsu PY, Pan MJ, Wu MS, Lee CH, Yu CC, et al. Clinical distinction and evaluation of leptospirosis in Taiwan—a case-control study. J Nephrol. 2005 Jan-Feb; 18(1):45–53. PMID: 15772922. Epub 2005/03/18. eng.

16. Abgueguen P, Delbos V, Blanvillain J, Chennebault JM, Cottin J, Fanello S, et al. Clinical aspects and prognostic factors of leptospirosis in adults. Retrospective study in France. J Infect. 2008 Sep; 57 (3):171–8. https://doi.org/10.1016/j.jinf.2008.06.010 PMID: 18656263.

17. Rajapakse S, Weeratunga P, Niloofa R, Fernando N, de Silva NL, Rodrigo C, et al. A Diagnostic Scoring Model for Leptospirosis in Resource Limited Settings. PLoS Negl Trop Dis. 2016 Jun; 10(6):e0004513. https://doi.org/10.1371/journal.pntd.0004513 PMID: 27333195.

18. Sitprija V, Losuwannak K, Kanjanabuch T. Leptospiral nephropathy. Semin Nephrol. 2003 Jan; 23 (1):42–8. PMID: 12563600.

19. Reis EA, Hagan JE, Ribeiro GS, Teixeira-Carvalho A, Martins-Filho OA, Montgomery RR, et al. Cyto-kine response signatures in disease progression and development of severe clinical outcomes for leptospirosis. PLoS Negl Trop Dis. 2013; 7(9):e2457. https://doi.org/10.1371/journal.pntd.0002457 PMID: 24069500.

20. Sitprija V, Pipatanagul V, Mertowidjojo K, Boonpucknav S. Pathogenesis of renal disease in leptospirosis: Clinical and experimental studies. Kidney Int. 1980 Jun; 17(6):827–36. PMID: 7412114.

21. Lecour H, Miranda M, Magro C, Rocha A, Goncalves V. Human leptospirosis—a review of 50 cases. Infection. 1989 Jan-Feb; 17(1):8–12. PMID: 2921094.

22. Visith S, Kearthit P. Nephropathy in leptospirosis. J Postgrad Med. 2005 Jul-Sep; 51(3):184–8. PMID: 16333190.

23. Araujo ER, Seguro AC, Spichler A, Magaldi AJ, Volpini RA, De Brito T. Acute kidney injury in human leptospirosis: an immunohistochemical study with pathophysiological correlation. Virchows Arch. 2010 Apr; 456(4):367–75. https://doi.org/10.1007/s00428-010-0894-8 PMID: 2017429.

24. Sitprija V. Altered fluid, electrolyte and mineral status in tropical disease, with an emphasis on malaria and leptospirosis. Nat Clin Pract Nephrol. 2008 Feb; 4(2):91–101. https://doi.org/10.1038/ncpneph0695 PMID: 1827802.

25. Liamis G, Milionis HJ, Elsaf M. Hyponatremia in patients with infectious diseases. J Infect. 2011 Nov; 63(5):327–35. https://doi.org/10.1016/j.jinf.2011.07.013 PMID: 21835196.

26. Dolthnikoff M, Mauad T, Bethlem EP, Carvalho CR. Pathology and pathophysiology of pulmonary manifestations in leptospirosis. Braz J Infect Dis. 2007 Feb; 11(1):142–8. PMID: 17625743.

27. Paganin F, Bourdin A, Dalban C, Courtin JP, Poubneau P, Borgherini G, et al. Leptospirosis in Reunion Island (Indian Ocean): analysis of factors associated with severity in 147 confirmed cases. Intensive Care Med. 2007 Nov; 33(11):1959–66. https://doi.org/10.1007/s00134-007-0776-y PMID: 17639339.

28. Andrade L, Rodrigues AC Jr., Sanches TR, Souza RB, Seguro AC. Leptospirosis leads to dysregulation of sodium transporters in the kidney and lung. Am J Physiol Renal Physiol. 2007 Feb; 292(2):F586–92. https://doi.org/10.1152/ajprenal.00102.2006 PMID: 16940563.

29. Zschiedrich S, Fischer KG. Severe Weil’s syndrome complicated by hemolytic anemia. Int J Infect Dis. 2010 Feb; 14(2):e181–2. https://doi.org/10.1016/j.ijid.2009.03.032 PMID: 19574076.

30. Chierakul W, Tientadakul P, Suputtamongkol Y, Wuthiekanun V, Phimda K, Limpaiboon R, et al. Activation of the coagulation cascade in patients with leptospirosis. Clin Infect Dis. 2008 Jan 15; 46(2):254–60. https://doi.org/10.1086/524664 PMID: 18171258.